4Szer D, Niemoller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hemotol, 2000,24 : 574- 576.
5Quilitz R,Pharm D. Thalidomide in oncology :the peril and the promise. Cancer control, 1999,6(5) :483-495.
6Figg WD,Raje S, Baner KS, et al. Pharmocokinetics of the thalidomide in an elderly protate cancer population. J Pharm Sci ,1999,88(1) : 121-125.
7DAmato R J, Loughnan MS, Flyyn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA, 1991,91 : 4082-4085.
8Liu J, Razani B, Tang S, et al. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenisis inhibitors block vascular endothelial growth factor-induced down-regulation of caveoline-1. J Biol, Chem, 1999, 274 (22):15781-15785.
9Schreibers A J, Obermair A. Multiple myeloma with election of chromosome is characterized by increased bone marrow neovascularization. Br J Heamotol, 2000,110 : 605 - 609.
10Rajkumar SV, leong T, Roche PC, et al . Progonstic value of bone marrow angiogensis in multiple myeloma. Clin Cancer Res,2000,6:3111 -3116.
